OPCI NY 2021

A senior consultant & interventional cardiologist at Lisie Heart Institute, Kochi, India. Features in 1 video on Wondr Medical. Rony Mathew generally speaks on Coronary Optical Coherence Tomography (OCT) and Bifurcation.

A director of cardiology at The Institute of Cardio-Vascular Diseases, Madras Medical Mission, Chennai, India. Features in 2 videos on Wondr Medical. S Ajit Mullasari generally speaks on Fractional Flow Reserve (FFR), Instantaneous wave-Free Ratio (iFR), Coronary Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS), and Rotational Atherectomy (PVD).

A chairman of interventional cardiology at Medanta Medicity Hospital, Gurgaon, India. Features in 1 video on Wondr Medical. Balbir Singh generally speaks on Coronary Optical Coherence Tomography (OCT) and Left Main Stem (LMS).

Dr. Singh is an Associate Professor of Medicine, Medical Director, Cardiac Catheterization Laboratory at Barnes-Jewish Hospital and Director of Interventional Cardiology. He specializes in coronary and peripheral vascular interventional procedures and spends most of his time in the cardiac catheterization laboratory. His expertise is in complex coronary intervention and also the endovascular treatment of renovascular hypertension, and peripheral arterial occlusive diseases. In addition, he has been involved in research ranging from new coronary devices to intravascular ultrasound and pressure/flow assessment of coronary vessels. He is the Principal Investigator in several high profile multicenter trials evaluating the above. He is actively involved in resident/fellow education and rotate in the coronary care unit twice a year. He has two interventional fellows per year who work closely with him during their training, he also serves as their attending in ½ day in patient clinic. He has second and third year cardiology fellows involved in clinical research protocols in the cath lab and their work has produced three instrumental abstracts/papers which in the first 12 months were presented at major cardiovascular society meetings. Dr. Singh is also the Chairman of ARCH, one of the largest Midwest Interventional Symposium.

Dr. Rao is Professor of Medicine at Duke University Medical Center, and the Section Chief of Cardiology at the Durham VA Medical Center. At the national level, Dr. Rao serves as the Editor-in-Chief for Circulation Cardiovascular Interventions, the interventional journal of the American Heart Association’s flagship Circulation family of journals. He is the President-Elect for The Society for Cardiovascular Angiography and Interventions, and serves on the program committees of the ACC Scientific Sessions, the Transcatheter Cardiovascular Therapeutics conference, and the SCAI Scientific Sessions. He was the chairman of the 2017 ACC-i2 Summit and was the chair of the SCAI 2019 Annual Scientific Session. In addition, he was the Editor-in-Chief of the ACC CathSAP 5 program and is currently the co-chair of the ACC Collaborative Management Pathway for Interventional Cardiology. His main research interests are pharmacological and interventional therapies for acute coronary syndromes, as well as bleeding and blood transfusion complications among patients with ischemic heart disease. Dr. Rao has published over 300 peer-reviewed papers, and is the co-Editor-in-Chief of the seminal textbook on transradial procedures titled “Best Practices for Transradial Approach in Diagnostic Angiography and Intervention.”

Ron Waksman, MD, FACC, Associate Director, Division of Cardiology, MedStar Washington Hospital Center (MWHC) and Director of Cardiovascular Research and Advanced Education for the MedStar Heart and Vascular Institute at the MedStar Washington Hospital Center. With nearly 20 years of experience in leading edge medical technologies, Dr. Waksman is a world-renowned interventional cardiologist and is a highly sought after Principal Investigator for pre-clinical and clinical studies conducted in the United States and abroad. Dr Waksman has performed over 5000 coronary interventions throughout his career.

Dr. Farouc Jaffer graduated from Stanford University in 1990 with a B.S. in Mathematical and Computational Sciences, and received in MD and PhD in Biophysics from the University of Pennsylvania of Medicine in 1996. He completed a residency in internal medicine at the Brigham and Women's Hospital, followed by a fellowship in cardiovascular medicine and interventional cardiology at Massachusetts General Hospital. In 2003, he joined the Cardiology Division as faculty. Dr. Jaffer is currently an Associate Professor of Medicine at Harvard Medical School and an Attending Interventional Cardiologist at Massachusetts General Hospital. He is Director of Coronary Intervention and Director of the Chronic Total Occlusion (CTO) PCI Program at at Massachusetts General Hospital. The MGH is a leading center for treating the most complex coronary blockages, such as CTO. Many patients, previously without options, have successfully underwent CTO PCI, and have experienced marked reductions in angina (chest pain) and shortness of breath. Dr. Jaffer is also a Principal Investigator in the MGH Cardiovascular Research Center where his NIH-funded laboratory develops novel molecular imaging approaches to image high-risk plaques and blood clots, to better prevent heart attacks, strokes, and venous blood clots.

Hiram Bezerra, MD, PhD, is Director, Cardiovascular Imaging Core Laboratory as well as Director, Director, Advanced Coronary and MCS at University Hospital Cleveland Medical Center. He is also an Associate Professor, Medicine at Case Western Reserve University School of Medicine. Previously, he served at Massachusetts General Hospital with extensive expertise in Cardiac Imaging, Interventional Cardiology, Optical Coherence Tomography and Computed Tomography.

Paul Teirstein, MD, is the Chief of Cardiology and Director of Interventional Cardiology for Scripps Clinic and Director of the Scripps Prebys Cardiovascular Institute for Scripps Health. With a primary focus on complex coronary interventions and new technology development, Dr. Teirstein has played an active role in the initial development and clinical investigation of coronary stent procedures, rotablator atherectomy, coronary angioscopy and the utilization of cardiopulmonary support. Dr. Teirstein pioneered the first effective treatment for restenosis (low dose radiation therapy) and was one of the early investigators of medicated and bioabsorbable stents. Recent areas of investigation include new technology for minimally invasive transcatheter aortic valve replacement (TAVR). Dr. Teirstein currently performs in excess of 800 stent procedures per year and maintains an active clinical research and teaching unit at Scripps Clinic where he strives to offer patients the most advanced cardiovascular care available worldwide.

Ki Park, MD, is a clinical assistant professor of medicine in interventional cardiology. In addition to her professorship role, she is the director of women’s cardiovascular health at UF Health. Dr. Park received a bachelor’s degree in microbiology at the University of Florida. She also completed her internal medicine residency, general cardiology fellowship and interventional cardiology fellowship at the University of Florida College of Medicine. During her fellowship training, she also completed a Cardiovascular Cell Therapy Research Network Fellowship and earned a master of science in translational science through the APPCI program. In 2010, she received the UF Department of Medicine’s Excellence in Research Award as well as the American Heart Association’s Women in Cardiology Trainee Award for Excellence. Dr. Park partners with other UF Health cardiologists to create a dedicated team for targeted cardiovascular women’s care in Gainesville and throughout Florida. She has a number of research studies focused on women-specific cardiology care to help offer the latest technologies and research to her patients.

Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory at St. Francis Hospital in Roslyn, New York. He is also a member of the Cardiovascular Research Foundation in New York City where he currently serves as the Director of the Physiology Core Laboratory. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high volume interventional cardiologist since 2006 and recognized as a Top Doctor in the New York Metro Area by Castle Connolly. Dr. Jeremias has significantly contributed to advancing the field of interventional cardiology and he is considered one of the foremost authorities in coronary physiology and intravascular imaging. He is a co-director of the annual St. Francis Intravascular Imaging and Coronary Physiology Workshop, teaching physicians around the world on “Precision Angioplasty”. Dr. Jeremias is presently engaged in a major global study that could change the path of treating clogged arteries. Known as the ILUMIEN IV trial, this major clinical study is evaluating Optical Coherence Tomography (OCT) to guide coronary stent placement. He is also the principal investigator of DEFINE PCI, an international study on assessing the improvement in blood flow after stent placement for severe coronary blockages.

Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial.

Dr. Riley is an Interventional Cardiologist specializing in the care of patients with complex and high-risk coronary artery disease and cardiogenic shock. He focuses on the treatment of coronary chronic total occlusions, multivessel coronary artery disease (including patients turned down for CABG surgery), atherectomy, and those in need of mechanical circulatory support. He was born in Knoxville, TN and completed his undergraduate education at Furman University with a degree in Chemistry. He attended medical school at the University of Virginia and completed residency in Internal Medicine at the University of Washington. He then completed his Cardiology fellowship at Wake Forest University, during which he obtained a Masters degree in Clinical and Population Translational Science. He then returned to the University of Washington to complete his Interventional Cardiology fellowship, followed by the first ever advanced fellowship in Complex, High-Risk, and Indicated PCI and Hemodynamic Support before joining the group at Christ Hospital. He is very active in clinical research, co-edits a monthly newsletter on high-risk PCI, and enjoys speaking at national and international meetings.

Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory at St. Francis Hospital in Roslyn, New York. He is also a member of the Cardiovascular Research Foundation in New York City where he currently serves as the Director of the Physiology Core Laboratory. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high volume interventional cardiologist since 2006 and recognized as a Top Doctor in the New York Metro Area by Castle Connolly. Dr. Jeremias has significantly contributed to advancing the field of interventional cardiology and he is considered one of the foremost authorities in coronary physiology and intravascular imaging. He is a co-director of the annual St. Francis Intravascular Imaging and Coronary Physiology Workshop, teaching physicians around the world on “Precision Angioplasty”. Dr. Jeremias is presently engaged in a major global study that could change the path of treating clogged arteries. Known as the ILUMIEN IV trial, this major clinical study is evaluating Optical Coherence Tomography (OCT) to guide coronary stent placement. He is also the principal investigator of DEFINE PCI, an international study on assessing the improvement in blood flow after stent placement for severe coronary blockages.

Ziad Ali is the Director of the DeMatteis Cardiovascular Institute, Director of Investigational Interventional Cardiology, and Director of Cardio-nephrology at St Francis Hospital & Heart Center in New York. He is also Director of the Angiographic Core Laboratory at Cardiovascular Research Foundation and Associate Professor of Medicine at Columbia University Medical Center. His clinical research interests focus on the use of intravascular imaging and physiology technologies such as optical coherence tomography, intravascular ultrasound, and flow wire assessment to optimize coronary interventions, for which he has served as a Global principal investigator on a number of trials. Dr. Ali is also a recognized innovator, playing an integral role in the development of the Resting Full-Cycle Ratio (RFR) and Shockwave intravascular lithotripsy. Clinically Dr. Ali developed pioneering techniques to perform vascular interventions without contrast administration, including IVUS-guided zero-contrast PCI and OCT using saline flush media, protecting patients with advanced kidney disease from acute kidney injury and the need for dialysis.

Dr. Kern is Chief of Medicine, VA Long Beach Health Care System, Professor of Medicine, University California, Irvine. He continues to perform and teach cardiac catheterization and PCI. Dr. Kern is ABIM Certified in Internal Medicine, Cardiovascular Diseases and Interventional Cardiology and is a past president and now a Master Fellow of the SCAI. His research interests in coronary blood flow, intravascular physiology, intravascular ultrasound, vulnerable plaque and evaluation of cardiovascular hemodynamics. He has authored several textbooks, notably The Cardiac Catheterization Handbook, 6th ed. and its companion The Interventional Cardiac Cath Handbook, 4th ed.

Dr. William Fearon graduated from Dartmouth College and received his medical degree from Columbia University College of Physicians and Surgeons, where he was elected into the Alpha Omega Alpha Medical Honor Society. He completed an Internal Medicine residency at Stanford University Medical Center serving an extra year as a Medical Chief Resident. He completed a General Cardiology and Interventional Cardiology fellowship at Stanford, spending his third year as the Chief Cardiology Fellow. He is currently a Professor of Cardiology and Director of Interventional Cardiology at Stanford University School of Mediciner. Dr. Fearon is board certified in cardiovascular medicine and interventional cardiology, and he is a fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiovascular Angiography and Interventions. He has been elected to the American Society for Clinical Investigation. Dr. Fearon’s primary area of research interest is in coronary physiology. He was the US principal investigator and senior author of the FAME trial, published in the New England Journal of Medicine and was a co-principal investigator and senior author of the FAME 2 trial, also published in the New England Journal of Medicine. He is now the principal investigator of the international FAME 3 trial comparing bypass surgery to fractional flow reserve guided percutaneous coronary intervention. He serves on the editorial board of the Journal of the American College of Cardiology, Circulation, JACC Cardiovascular Interventions, and Circulation: Cardiovascular Interventions. He was the principal investigator on an R01 and is the PI on an R61/R33 NIH award evaluating cardiac allograft vasculopathy early after transplantation. Dr. Fearon’s clinical activities include not only percutaneous coronary intervention, but also transcatheter aortic valve replacement. He was a coauthor on the PARTNER 2A Trial published in the New England Journal of Medicine.

Amir Kaki is a consultant/attending.

Director of Rescue the Heart Program, Director CTO, and Advanced Coronary Therapeutics, Morristown Medical Center Dimitrios Karmpaliotis, MD, PhD, FACC, FSCAI is Medical Director of the Cardiovascular Rescue and Recovery Program and the Advanced Coronary Therapeutics and Chronic Total Occlusions Program at Morristown Medical Center. Dr. Karmpaliotis was formerly at the Center for Interventional Vascular Therapy at Columbia University Medical Center, where he provided world-class care since 2014. He is a former associate professor of medicine at Columbia University Medical School and formerly served as director of the Chronic Total Occlusions, Complex and High-Risk Angioplasty Program at New York-Presbyterian/Columbia University Medical Center.

Dr. David E. Kandzari is the Chief of the Piedmont Heart Institute and Cardiovascular Service Line; Director, Interventional Cardiology of the Piedmont Heart Institute; and Chief Scientific Officer for Piedmont Healthcare in Atlanta, Georgia. Dr. Kandzari specializes in cardiovascular disease, peripheral arterial disease and interventional cardiology. A graduate of Duke University School of Medicine, he completed his internship and residency at The John Hopkins University School of Medicine in Baltimore, Maryland. Following his residency, he completed his general and interventional cardiology fellowship at Duke University where he joined the faculty as the John B. Simpson Assistant Professor of Interventional Cardiology and Genomic Sciences. Dr. Kandzari is the former Director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, California. Before joining the Scripps faculty, he also served as Chief Medical Officer for the Cordis Corporation, a Johnson & Johnson Company. He has also served as a Medical Officer for the Center for Devices and Radiological Health for the United States Food and Drug Administration. Board certified by the American Board of Internal Medicine and its subspecialty Board of Cardiovascular Disease and Board of Interventional Cardiology, Dr. Kandzari has held national and international leadership roles in clinical trials in cardiovascular disease and has participated in national and international program committees in cardiology. He has authored and coauthored more than 400 studies, book chapters and scientific reviews, and has delivered more than 700 lectures, both nationally and internationally, on a variety of issues related to both interventional and general cardiology. Dr. Kandzari has been consecutively voted as one of Atlanta's Top Doctors by Atlanta Magazine from 2011 to 2021, and is peer-nominated in the top 1% of cardiologists by U.S News and World Report.

Dr Stéphane Rinfret is an academic interventional cardiologist and world-renown expert in chronic total occlusion (CTO) percutaneous coronary intervention (PCI). He was appointed chief of interventional cardiology at the McGill University Health Centre (MUHC) and associate professor of medicine at McGill University in 2016 where he built a very active chronic total occlusion (CTO) and Complex Higher-risk but Indicated Procedures (CHIP) program. He has now moved to the US to work with at Emory Healthcare and Emory University, as associate-director of complex PCI and full professor (acting) of Medicine, to pursue his academic career and busy clinical practice, mostly at Emory Saint Joseph's Hospital, the oldest hospital of Atlanta serving a very large population. Dr Rinfret has held several peer-reviewed grants, published over 150 peer-reviewed articles, several abstracts, and has been invited over 300 times to give lectures in the last 10 years. His epidemiological research focuses on health services and outcomes. He is also a high-volume and world-renown coronary operator, performing over 400 percutaneous coronary interventions (PCIs) per year, mostly from the transradial approach and most with complex anatomies. Dr Rinfret was one of the Canadian pioneers in CTO PCI and has contributed to expand access to the technique in Canada and all around the world through sharing his expertise. He is the lead editor of a textbook on CTO PCI published by Springer in 2015, currently being reviewed for a second edition. He has performed over 1200 CTO PCIs since January 2010, one of the largest volumes in the world, including a large number of retrograde procedures, and pursues a very active teaching program of transradial and CTO PCI techniques in Canada and Europe.

Works at Montefiore Medical Center, New York, NY, US. Features in 40 videos on Wondr Medical. Azeem Latib generally speaks on Bioresorbable Vascular Scaffold (BVS), Drug Eluting Stents (DES), Intravascular Ultrasound (IVUS), Bifurcation, and Intracoronary Imaging.

Dr. Michael S. Lee, is an interventional cardiologist, Associate Professor of Medicine and the Associate Director of Interventional Cardiology Research at the UCLA Medical Center. Dr. Lee has published over 110 (over 70 of which were as first author) peer reviewed articles and chapters. He has also published on topics including antithrombotic therapy in patients with acute coronary syndrome and in percutaneous coronary intervention, protocols to establish heparin dosing regimens, and percutaneous coronary intervention for the treatment of left main disease, saphenous vein grafts, and cardiac allograft vasculopathy who have undergone orthotopic heart transplantation. He is one of the world’s authorities in coronary and peripheral orbital atherectomy.

An internationally recognized interventional cardiologist, Dr. Moses has performed more than 15,000 interventional procedures, authored over 600 publications, and served as lead investigator for numerous national and international clinical studies that have demonstrated the effectiveness and safety of coronary stent placement. In 2002, Dr. Moses was the lead investigator on a large clinical trial, the first in the U.S. that demonstrated the enormous benefit that led to FDA approval of the first drug-coated stent now used in the majority of interventional procedures in the U.S. Most recently in on the Executive Committee of PARTNER trial; they brought the first transcatheter aortic valve to clinical use in the U.S. He currently serves as Director of Interventional Cardiovascular Therapeutics at Columbia University Medical Center and as Director of Advanced Cardiac Interventions at St Francis Hospital and Heart Center in Roslyn, NY. He is also a pioneer in developing approaches involving minimally invasive surgery, angioplasty, gene therapy, novel imaging technologies and various support devices that allow for wider application of interventional cardiovascular procedures.

Elazer Edelman works at MIT, Boston, MA, USA.

Ori Ben-Yehuda, is the Executive Director of the Clinical Trials Center at the Cardiovascular Research Foundation. A graduate of Tel Aviv University, he completed his fellowship in cardiology at the University of California, San Diego. From 1997 to 2011 he was the Director of the Coronary Care Unit at UCSD where he was also Professor of Medicine. He also served as the Deputy Editor of the Journal of the American College of Cardiology and is presently the Deputy Editor of Structural Heart: the Journal of the Heart Team. Dr. Ben-Yehuda is involved in the design and execution of multiple clinical trials in interventional cardiology.

Manesh Patel is the Chief of the Division of Cardiology and the Division of Clinical Pharmacology. His clinical interests include diagnostic and interventional coronary angiography, peripheral angiography and endovascular intervention. His is involved in several clinical trials involving patients with cardiovascular disease and in cardiac imaging. He is also the Chair of the American College of Cardiology Task Force for Appropriate Use Criteria for Cardiovascular Procedures and is Chair of the American Heart Association Diagnostic and Interventional Cath Committee. Patel's interest in cardiac imaging, quality of care, cardiac devices is also evident in his research. His integration of these efforts into his roles at Duke was recognized in 2010 when he received the prestigious Duke Cardiology Fellowship Mentor Award. In 2011, Dr. Patel was named the endowed John Bush Simpson Assistant Professor of Cardiology. In 2013, Dr. Patel received the Robert M. Califf Faculty clinical research Award. Currently, Dr. Patel is leading an effort to redesign the delivery of care to patients undergoing invasive catheterization procedures in the health system with a specific aim of measure and providing individualized, patient centered, innovative, and efficient care.

Gary S. Mintz, MD, is a Senior Medical Advisor at the Cardiovascular Research Foundation (CRF, New York, NY) and a Director of Transcatheter Cardiovascular Therapeutics (TCT). He is the author of more than 1000 peer reviewed articles, 60 book chapters, 4 books, and 850 abstracts concerning various aspects of clinical cardiology, cardiac ultrasound, hemodynamics, cardiac radiology and coronary arteriography, interventional cardiology, and (especially) intravascular imaging and physiology. In 2005, Dr. Mintz published his single-authored textbook Intracoronary Ultrasound that has now been translated into Chinese. In 2014, Dr. Mintz received the Master of the Masters Career Achievement Award at the TCTAP-Cardiovascular Summit in Seoul, Korea; in 2015 Dr. Mintz received the Chien Foundation Outstanding Lectureship & Lifetime Achievement Award, also presented at TCTAP-Cardiovascular Summit in Seoul, Korea; in 2017 Dr. Mintz received the Outstanding Achievement Award at CBS 2017, Nanjing, China; in 2018 Dr. Mintz received the Career Achievement Award at NFIC in Krakow, Poland; and in 2020 Dr. Mintz received the Jiangsu Friendship Award from the People’s Government of Jiangsu Province, China, the highest award presented to a non-Chinese. He also serves as a Senior Scientist and Advisor at the Medstar Cardiovascular Research Network, Washington, DC. Dr. Mintz completed his undergraduate education at the University of Pennsylvania in 1970 and received his medical degree from Hahnemann University (now part of Drexel University), in 1974, both in Philadelphia, PA. He finished his internship in 1975, residency in 1976, and cardiology fellowship in 1978, each at Hahnemann University. He joined the Hahnemann University Department of Medicine faculty in 1978 and was ultimately promoted to Professor of Medicine in 1987 before joining CRF in 1991. His past appointments at CRF have included Chief Medical Officer and Editor-in-Chief (and one of the founders) of TCTMD.com.

Works at CRF Skirball Center for Innovation, Orangeburg, NY, USA. Features in 13 videos on Wondr Medical. Juan Granada generally speaks on Mitral, Repair/Replacement, Trans Mitral Valve Implantation (TMVR), Mitral regurgitation, and Bioresorbable Vascular Scaffold (BVS).

Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory at St. Francis Hospital in Roslyn, New York. He is also a member of the Cardiovascular Research Foundation in New York City where he currently serves as the Director of the Physiology Core Laboratory. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high volume interventional cardiologist since 2006 and recognized as a Top Doctor in the New York Metro Area by Castle Connolly. Dr. Jeremias has significantly contributed to advancing the field of interventional cardiology and he is considered one of the foremost authorities in coronary physiology and intravascular imaging. He is a co-director of the annual St. Francis Intravascular Imaging and Coronary Physiology Workshop, teaching physicians around the world on “Precision Angioplasty”. Dr. Jeremias is presently engaged in a major global study that could change the path of treating clogged arteries. Known as the ILUMIEN IV trial, this major clinical study is evaluating Optical Coherence Tomography (OCT) to guide coronary stent placement. He is also the principal investigator of DEFINE PCI, an international study on assessing the improvement in blood flow after stent placement for severe coronary blockages.

David J. Cohen, MD, MSc is currently Director of Clinical and Outcomes Research at the Cardiovascular Research Foundation (New York, NY) and Director of Academic Affairs at St. Francis Hospital (Roslyn, NY). Previously, he was Professor of Medicine at the University of Missouri–Kansas City and Director of Cardiovascular Research and Medical Director of Health Economics and Technology Assessment at Saint Luke’s Mid America Heart Institute. Heart Institute where he continues to direct the Health Economics and Technology Assessment Group. Dr. Cohen earned his M.D. at Harvard Medical School and his Master's degree in Health Policy at the Harvard School of Public Health. He did his clinical training at Brigham and Women's Hospital and was a clinical and research fellow in cardiology at Beth Israel Hospital for five years. Dr. Cohen is a practicing interventional cardiologist with a focus on structural and valvular heart disease. His research focuses on the application of formal cost-effectiveness methodology to novel interventions for cardiovascular disease (CVD), the extension of traditional cardiovascular outcomes research to include patient-centered outcomes, and the development and evaluation of instruments for assessing CVD patients’ health status and preferences. He is also active in research to determine the short- and long-term outcomes of new devices for percutaneous coronary revascularization and identifying the optimal target populations and techniques for these devices. Dr. Cohen has published more than 500 original articles in leading journals, including the New England Journal of Medicine, Lancet, JAMA, Circulation, and the Journal of the American College. Dr. Cohen serves on the editorial board for the American Heart Journal, JACC Interventions, and Circulation and reviews for the American Journal of Cardiology, Journal of the American College of Cardiology, New England Journal of Medicine, JAMA, and Medical Decision Making.

Dr. Evan Shlofmitz is an Interventional Cardiologist and the Director of Intravascular Imaging at St. Francis Hospital - The Heart Center in Roslyn, NY. He completed a fellowship in Interventional Cardiology at Georgetown University/MedStar Washington Hospital Center. He previously completed an Intravascular Imaging and Physiology fellowship at the Cardiovascular Research Foundation (CRF) and Columbia University Medical Center (CUMC), a Cardiovascular Disease fellowship at Northwell Health and served as Chief Resident for Internal Medicine at New York Presbyterian Queens. He serves on SCAI's IHD Council and is a co-director of Optimizing PCI (OPCI). His research interests have centered on intravascular imaging, the treatment of calcified coronary artery disease, in-stent restenosis and the optimization of stent implantation, with more than 100 publications in peer-reviewed journals.

An internationally recognized interventional cardiologist, Dr. Moses has performed more than 15,000 interventional procedures, authored over 600 publications, and served as lead investigator for numerous national and international clinical studies that have demonstrated the effectiveness and safety of coronary stent placement. In 2002, Dr. Moses was the lead investigator on a large clinical trial, the first in the U.S. that demonstrated the enormous benefit that led to FDA approval of the first drug-coated stent now used in the majority of interventional procedures in the U.S. Most recently in on the Executive Committee of PARTNER trial; they brought the first transcatheter aortic valve to clinical use in the U.S. He currently serves as Director of Interventional Cardiovascular Therapeutics at Columbia University Medical Center and as Director of Advanced Cardiac Interventions at St Francis Hospital and Heart Center in Roslyn, NY. He is also a pioneer in developing approaches involving minimally invasive surgery, angioplasty, gene therapy, novel imaging technologies and various support devices that allow for wider application of interventional cardiovascular procedures.

Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial.

Ziad Ali is the Director of the DeMatteis Cardiovascular Institute, Director of Investigational Interventional Cardiology, and Director of Cardio-nephrology at St Francis Hospital & Heart Center in New York. He is also Director of the Angiographic Core Laboratory at Cardiovascular Research Foundation and Associate Professor of Medicine at Columbia University Medical Center. His clinical research interests focus on the use of intravascular imaging and physiology technologies such as optical coherence tomography, intravascular ultrasound, and flow wire assessment to optimize coronary interventions, for which he has served as a Global principal investigator on a number of trials. Dr. Ali is also a recognized innovator, playing an integral role in the development of the Resting Full-Cycle Ratio (RFR) and Shockwave intravascular lithotripsy. Clinically Dr. Ali developed pioneering techniques to perform vascular interventions without contrast administration, including IVUS-guided zero-contrast PCI and OCT using saline flush media, protecting patients with advanced kidney disease from acute kidney injury and the need for dialysis.

Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial.